Treatment of Alzheimer's anti-Tau vaccine starts phase 1b/2a trial.

Ac Immune SA, a Swiss-based clinical biopharmaceutical company, has announced it will launch a Phase 1b/2a clinical trial of its ACI-35.030 higher dose group of the Alzheimer's vaccine, following encouraging data on vaccine safety, tolerance and immunogenicitycurrently, anti-Tau vaccines have become an important treatment strategy for AD and other neurodegenerative diseases characterized by TauThe main pathological symptoms ofAD are two ways, one is the abnormal deposition of beta-amyloid protein outside neuronal cells to form the age spots, and the other is the abnormal phosphorylation of Tau protein, which forms neuronal fibrosisa large number of abnormal Tau proteinin in the brain of patients with AD, and abnormal modification and content changes of Tau protein play an important role in the pathology of the diseaseACI-35.030 anti-pTau active vaccine, using lipids as a vaccine immune adjure, can reduce and promote the removal of Tau aggregates in patients, slow down the Tau pathology process, and treat potential tau protein diseaseACI-35.030 is an Alzheimer's vaccine candidate developed by AC Immune in collaboration with Xi'an Jansen, an anti-pTau active vaccine with liposomes as an immunoassomed, which reduces and promotes the removal of Tau aggregates in patients, slows down the Tau pathology process, and treats potential tau protein diseaseACI-35.030 showed encouraging safety and immunogenicity in the lowest-dose of older subjects,, according to, according to a, according to, chief executive, AC Immune SATau-targeted treatments may have a wider range of treatments that can potentially disrupt, slow or prevent disease progression in the early and late stages of the diseaseusually, pathological pTau occurs early in the disease process, a few years before Tau deposits accumulate in the patient's brain, so the method of targeting pTau is expected to treat AD at different stages of the diseasethis phase 1b/2a clinical trial is a randomized, multicenter, double-blind, placebo-controlled clinical study with the primary purpose of assessing the safety, tolerance and immunogenicity of early AD patients after receiving different doses of ACI-35.030Other endpoints of thetrial include assessing improvements in clinical and cognitive conditions, as well as other immunogenicity and safety dataReference source: AC Immune Advances phospho-Tau Alzheimer's Phase Vaccine 1b/2a Study.